



One Command Center.

A trillion possibilities for precision.

Kintai Therapeutics, Inc. is uniquely focused on unlocking the power of the enteric signaling network and its signals throughout the body to fight disease and restore the health of patients.

Pioneering Science

Kintai has pioneered a new frontier in gut science based on its multidisciplinary approach which integrates the microbiome, gut immune system, and enteric nervous system and their roles in human health. Kintai is leveraging its unprecedented mapping of the entire enteric system and integrate multi-omics data to elucidate the richness and regio-specificity of microbes, genes, enzymes and metabolites within the human body. Utilizing these data and through the company's extensive expertise in human biology, experimental medicine, bioinformatics and machine learning, Kintai has created a discovery and therapeutic development approach to rapidly identify and deliver a new class of medicines called Precision Enteric Medicine™ (PEM™) compounds. The company's versatile technology platform enables a rich pipeline of programs across multiple therapeutic areas, including oncology, neurology, metabolic disease and immunology. The company also pursues partnerships with premier academic institutions, industry and individual key opinion leaders to coalesce the leading minds across the biomedical ecosystem to advance breakthrough medicines.

Unlocking the Power of the Enteric Signaling Network

The human gut houses 70-80% of immune cells, 500 million neurons and trillions of bacteria. This rich and diverse community of cells, otherwise known as the enteric signaling network, acts as a command center by transmitting information throughout the body that can affect propensity for disease.



Kintai has achieved a groundbreaking understanding of the enteric signaling network, including new genes, metabolites, and signaling molecules within the body. The company has discovered over 44,000 new genes and hundreds of new metabolites. Leveraging these insights, Kintai is rapidly translating these discoveries into a highly actionable pipeline.

GENETIC

>44,000

newly discovered genes

BIOCHEMICAL

>19,000

protein families localized in the GI tract, including over 6000 enzymes

METABOLITE

>400

previously uncharacterized compounds

Precision Enteric Medicine™ Compounds

Kintai is leveraging the body's robust signaling networks to pioneer Precision Enteric Medicine™ (PEM™) compounds, a new class of small molecule-based medicines to treat a broad range of diseases in a more effective, optimized way. The company is utilizing its unique human biosamples and applying its proprietary technologies, consisting of high dimensional measurements and integrated analytics, for the rapid identification of therapeutically relevant and novel targets, bioactive compounds and biomarkers.

PEM™ compounds are designed to modulate disease in a number of ways, depending on root cause:

Amplify

Modulate signaling networks to convert non-responders to responders

Leverage

Utilize bacterial machinery to activate at the site of lesions

Inhibit

Limit aberrant bacterial metabolism

Restore

Reset the natural balance in the body by delivering beneficial metabolites

Robust Pipeline Portfolio

Today, Kintai has an extensive portfolio of programs underway that are focused across multiple therapeutic areas, including oncology, neurology, metabolic disease and immunology, to bring innovative medicines to patients in need. Kintai's integrated discovery approach is not restricted to certain therapeutic areas, but rather, led by the science. The company credits the speed and accelerated pace of its scientific advancements to 1) its extremely creative and dedicated multidisciplinary team, 2) its innovative approach to develop small molecule medicines, 3) the recent revolution in the microbiome space which has expanded understanding of the gut community and 4) the company's unique and proprietary focus on the enteric signaling network and its interconnectivity across the body.



Exploratory Areas:

Oncology

Epilepsy

Parkinson's Disease

“Our philosophy at Kintai is that medical breakthroughs are most likely to occur through a collation of leading minds across the biomedical ecosystem. We have attracted top talent to work at Kintai, and we are also augmenting our capabilities by working with premier academic institutions to propel advancements on behalf of patients.”

Paul-Peter Tak, M.D., Ph.D.

President and CEO, Kintai



About Kintai

Kintai Therapeutics is uniquely focused on unlocking the power of the enteric signaling network and its signals throughout the body to fight disease and restore health. The company's unprecedented knowledge of the interconnectivity of gut microbiota, immune cells, and neurons and their role in extended wellness and pathology has led to the advancement of a new class of medicines, Precision Enteric Medicine™ (PEM™) compounds.

Kintai believes that its core strength lies in the hearts and minds of its talented employees who always keep patients at the center. Kintai was founded in 2016 by Flagship Labs, the innovation foundry of Flagship Pioneering.

Leadership

Paul-Peter Tak, M.D., Ph.D.

President and Chief Executive Officer

Mark E. Nuttall, Ph.D.

Chief Business Officer

Kristen Bridge

Senior Vice President of Strategy and Portfolio

Robert Holman

Vice President of Finance

Lisa Fiering

Vice President of Human Resources

Marina Volin

Vice President of Legal and Intellectual Property

Steven J. Taylor, Ph.D.

Senior Vice President of Research and Innovation

Leonard Buckbinder, Ph.D.

Vice President of Biology

Francesca Barone, M.D., Ph.D.

Vice President of Experimental Medicine



www.kintaitx.com

For more information contact us at
info@kintaitx.com

Kintai Therapeutics, Inc. © 2020 – All rights reserved.